


Pharmaceuticals & Biotechnology | Small Cap
Shilpa Medicare Ltd operates within the Healthcare Services sector. The company shows mixed financial results. Growth in revenue and operating profit is a positive sign, alongside a strong solvency position. However, there are some concerns with the company's efficiency and liquidity. The company's profitability metrics are generally strong. The company's financial ratios present a mixed picture, with strengths in book value per share but weaknesses in dividend and capital expenditure management. The company's growth shows positive momentum in certain areas but also highlights significant challenges in earnings and net income. Overall, Shilpa Medicare demonstrates a blend of financial strengths and weaknesses that warrant attention.
Shilpa Medicare Ltd operates within the Healthcare Services sector. The company shows mixed financial results. Growth in revenue and operating profit is a positive sign, alongside a strong solvency position. However, there are some concerns with the company's efficiency and liquidity. The company's profitability metrics are generally strong. The company's financial ratios present a mixed picture, with strengths in book value per share but weaknesses in dividend and capital expenditure management. The company's growth shows positive momentum in certain areas but also highlights significant challenges in earnings and net income. Overall, Shilpa Medicare demonstrates a blend of financial strengths and weaknesses that warrant attention.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
108.65
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
59.39
P/B RATIO
5.60
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
9.56
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
5.53
EV/EBITDA RATIO
31.33
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹738.8 as on Aug 6, 2026.
The growth ratios show a mixed performance. While revenue and operating profit growth rates are strong, earnings per share (EPS) and net income growth rates are negative. This suggests that the company is growing its top line but struggling to convert it into bottom-line profits. The company has been doing well in terms of revenue and operating profit, but not in terms of earnings.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 26.92 | -8.33 | 9.56 | 11.78 | 20.14 |
| Operating Profit Growth Rate | 11.6 | -50.99 | 141.41 | 32.22 | 37.66 |
| Earnings Per Share (EPS) Growth | -61.48 | -153.58 | -198.4 | 117.39 | 211 |
| Asset Growth Rate | 9.27 | 0.97 | 6.51 | 7.05 | 11.93 |
| Net Income Growth Rate | -58.22 | -150.82 | -203.23 | 143.75 | 211.54 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC Ltd | 7.64 | 22.41 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 35.17 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 35.44 | Neutral | 369.00 | 19.43 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 38.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 41.09 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 29.35 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | Aarti Drugs Ltd | 7.20 | 19.31 | Undervalued | 309.00 | 18.54 | 195.00 |
| 8 | Hikal Ltd | 7.13 | -58.73 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | RPG Life Sciences Ltd | 7.12 | 38.88 | Neutral | 147.00 | 69.64 | 115.00 |
| 10 | SMS Pharmaceuticals Ltd | 5.94 | 33.48 | Neutral | 171.00 | 9.35 | 102.00 |
| 11 | Shilpa Medicare Ltd | 5.94 | 58.02 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 12 | Strides Pharma Science Ltd | 5.55 | 16.08 | Undervalued | 925.00 | 19.92 | 575.00 |
| 13 | Jeena Sikho Lifecare Ltd | 5.52 | 32.45 | Neutral | 349.00 | 17.87 | 222.00 |
| 14 | Gufic BioSciences Ltd | 5.49 | 61.62 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | Dishman Carbogen Amcis Ltd | 5.38 | 31.42 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 244.53 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 314.71 | Overvalued | 162.00 | 1.74 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.56 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Zota Health Care Ltd | 3.97 | -58.62 | Neutral | 19.00 | 8.06 | -74.00 |
| 20 | Procter & Gamble Health Ltd | 3.45 | 32.82 | Neutral | 457.00 | 196.94 | 327.00 |
| 21 | Sanofi India Ltd | 3.45 | 18.52 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish